In November 2019, the NIH hosted the first-ever conference dedicated to chronic rhinosinusitis with nasal polyps (CRSwNP). Clinical experts from allergy and otolaryngology, along with scientific researchers met to discuss current treatments for the disease and directions for future research.…
In this paper, Drs. Cho, Hamilos, Han, and Laidlaw review the diagnoses and treatments for different types of chronic rhinosinusitis (CRS) . The two most commonly described phenotypes of CRS are CRS with nasal polyps (CRSwNP) and CRS without nasal…
This review by Drs. Tanya M. Laidlaw and Kathleen M. Buchheit provides an update on the existing studies of biologics as treatments for nasal polyposis and identifies potential future areas for further research. Chronic rhinosinusitis with nasal polyposis, which is…
In this study, researchers at Brigham and Women’s Hospital demonstrated the feasibility and safety of a 1-day aspirin desensitization procedure. Desensitization remains the standard of treatment for patients with AERD but it has historically been time consuming—sometimes taking 2 to…
Aspirin-exacerbated respiratory disease: not always “adult-onset”. The AERD Center at Brigham and Women’s Hospital in Boston, MA collected a detailed clinical history from 227 patient with AERD within their AERD Patient Registry. Although AERD is generally considered to be a…
Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease. The AERD Center at Brigham and Women’s Hospital in Boston, MA collected clinical characteristics and biologic specimens from 29 patients with AERD undergoing an aspirin desensitization procedure. In addition to the…
Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. The AERD Center at Brigham and Women’s Hospital in Boston, MA identified a group of 7 AERD/Samter’s Triad patients with recurrent nasal polyps who, at the time of AERD…
Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. AERD/Samter’s Triad is recognized as a distinct asthma phenotype, but the recent work of Dr. Ewa Nizankowska-Mogilnicka and the late Dr. Andrzej Szczeklik, now sheds new insights on the…
Prostaglandin E2 (PGE2) deficiency results in AERD-like phenotype. AERD/Samter’s Triad is characterized by mast cell activation with overproduction of cysteinyl leukotrienes following inhibition of COX-1 by medications like aspirin or NSAIDs. The cause of the mast cell activation that occurs…